The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ImmunityBio
biotech company
Nothing else this week.
- FDA
Related events
- FDA approval expands patient access to therapies for ACCORD.
- Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.
- FDA provided guidance for HCW Biologics' IND application.
- OMB reviews a proposed FDA peptide rule while former chiefs criticize RIF efforts and Overton pushes vaccine reduction changes.
- FDA approved a new cancer drug in Massachusetts on October 21, 2026.
Coverage
Newest first; wire copies grouped- Insider MonkeyImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform We recently published 10 Best Biotech Stocks to Buy Under $10. ImmunityBio, Inc. is among them. ImmunityBio, Inc. (NASDAQ: